Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study

PURPOSE: Desmoid tumor, also known as aggressive fibromatosis, is well-characterized by abnormal Wnt/β-catenin signaling. Various therapeutic options, including imatinib, are available to treat desmoid tumor. However, the molecular mechanism of why imatinib works remains unclear. Here, we describe p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Joonha, Lee, Jun Hyeong, Lee, Young Han, Lee, Jeeyun, Ahn, Jin-Hee, Kim, Se Hyun, Kim, Seung Hyun, Kim, Tae Il, Yun, Kum-Hee, Park, Young Suk, Kim, Jeong Eun, Lee, Kyu Sang, Choi, Jung Kyoon, Kim, Hyo Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582486/
https://www.ncbi.nlm.nih.gov/pubmed/35038826
http://dx.doi.org/10.4143/crt.2021.1194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582486/
https://www.ncbi.nlm.nih.gov/pubmed/35038826
http://dx.doi.org/10.4143/crt.2021.1194

Ejemplares similares